BBSRC Industrial Studentship with Critical Pharmaceutical Ltd
Investigation Of A Novel Absorption Promoter For The Transmucosal Delivery Of Drugs
University of Nottingham - School of Pharmacy
The project will investigate a novel absorption promoter for the transmucosal delivery of drugs that is of interest to the industrial sponsor. This project will focus on a number of key areas including: evaluation of the physico-chemical properties of the absorption promoter formulations and identify essential characteristics, investigate its mechanisms of action using appropriate cell culture models and identifying synergistic effects with other known absorption promoters.
This PhD project will be supervised in collaboration with the academic supervisor (Dr S Stolnik) and industrial co-sponsor, Critical Pharmaceuticals Ltd (Dr F Jordan) and will provide the student with training in drug delivery, physicochemical characterisation, cell culture and related analytical and imaging methods, along with the opportunity to work in both an academic and industrial research surrounding.
Critical Pharmaceuticals is a biotechnology company with proprietary drug delivery technologies for injectable sustained release and nasal delivery of challenging drugs including proteins and peptides.
For more information see: http://www.criticalpharmaceuticals.com/.
The nasal route of delivery can be exploited for the systemic delivery of drugs such as small molecular weight polar drug, peptides and proteins that are not easily administered via other routes than by injection.
Despite the large surface area of the nasal cavity and extensive blood supply, absorption of polar molecules, peptides and proteins is low and can be greatly improved if administered in conjunction with an absorption promoting agent.
The enhancer systems work by a number of mechanisms, however, studies have shown that there is a direct correlation between the absorption enhancing effect obtained and the damage caused to the nasal membrane. It is therefore important to discover and evaluate new absorption promoter systems. Critical Pharmaceuticals is a small specialty pharmaceutical company and have developed a safe and effective nasal drug delivery platform based on an absorption promoter called CriticalSorbTM.
This is a four year BBSRC studentship co-funded with industry (Critical Pharmaceuticals Ltd).
To learn more about the project and/or to express an interest please contact Dr S Stolnik, Email: Snjezana.Stolnik@Nottingham.ac.uk, Dr F Jordan, Email: Faron.Jordan@Criticalpharmaceuticals.com or Mrs C MacLeod, tel: 0115 846 6250, Email: Christina.Macleod@Nottingham.ac.uk.
Please quote ref. SCI/807.
This studentship is open until filled.
For all our vacancies and more about working at the University of Nottingham see: http://jobs.nottingham.ac.uk/.
This PhD project will be supervised in collaboration with the academic supervisor (Dr S Stolnik) and industrial co-sponsor, Critical Pharmaceuticals Ltd (Dr F Jordan) and will provide the student with training in drug delivery, physicochemical characterisation, cell culture and related analytical and imaging methods, along with the opportunity to work in both an academic and industrial research surrounding.
Critical Pharmaceuticals is a biotechnology company with proprietary drug delivery technologies for injectable sustained release and nasal delivery of challenging drugs including proteins and peptides.
For more information see: http://www.criticalpharmaceuticals.com/.
The nasal route of delivery can be exploited for the systemic delivery of drugs such as small molecular weight polar drug, peptides and proteins that are not easily administered via other routes than by injection.
Despite the large surface area of the nasal cavity and extensive blood supply, absorption of polar molecules, peptides and proteins is low and can be greatly improved if administered in conjunction with an absorption promoting agent.
The enhancer systems work by a number of mechanisms, however, studies have shown that there is a direct correlation between the absorption enhancing effect obtained and the damage caused to the nasal membrane. It is therefore important to discover and evaluate new absorption promoter systems. Critical Pharmaceuticals is a small specialty pharmaceutical company and have developed a safe and effective nasal drug delivery platform based on an absorption promoter called CriticalSorbTM.
This is a four year BBSRC studentship co-funded with industry (Critical Pharmaceuticals Ltd).
To learn more about the project and/or to express an interest please contact Dr S Stolnik, Email: Snjezana.Stolnik@Nottingham.ac.uk, Dr F Jordan, Email: Faron.Jordan@Criticalpharmaceuticals.com or Mrs C MacLeod, tel: 0115 846 6250, Email: Christina.Macleod@Nottingham.ac.uk.
Please quote ref. SCI/807.
This studentship is open until filled.
For all our vacancies and more about working at the University of Nottingham see: http://jobs.nottingham.ac.uk/.
No comments:
Post a Comment